Zurueck zur Suche

Reporte zur Charge U007471

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

8Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
TX 2 NC 1 IA 1 WV 1 CA 1 AZ 1 IN 1

VAERS 1736937

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge u007471

mild
Staat
TX
Alter
8,0
Geschlecht
M
Eingang
27.09.2021
Impfdatum
24.09.2021
Beginn
24.09.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
SC / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Hypersensitivity Urticaria

Symptomtext

1503: Patient returns to area, mom lifts atient?s shirt to reveal hives on back and front of trunk, neck, and on upper arms. Pt also noted to be scratching. Patient AAO, respirations even/unlabored at 20/min, patient is calm with no s/s of distress. 1505: Area cleared, Vital signs taken, initiated close monitoring and observation for safety. 1508: Administered Benadryl 25mg chewable tablet PO 1511: Language line called, explained to mother that hives are an allergic reaction, that the patient is not in immediate danger or distress, and explained the medication administered and how it should help 1517: Vital signs taken and pt reassessed. Hives still visible, but no s/s of distress or increase in severity. Close monitoring continued. 1520: Notified Dr. of situation via phone, MD orders taken: 1. Follow procedures for moderate allergic reaction 2. Continue monitoring for 30 minutes, then evaluate ensure reaction is not progressing in severity. 1524: Onsite provider NP comes to area, evaluates patient. NP reinforces that patient is experiencing a mild reaction, and that it is safe for patient to leave clinic as reaction is not progressing in severity. 1529: Patient reassessed. Fewer hives visible, and those seen are noted to be smaller and less raised. Close monitoring continued. 1537: Program manager contacted via phone and briefed on situation. 1545: Spoke with parent again via language line iinterpreter.Educated parent on hives as an allergic reaction, medication given as treatment, s/s of anaphylaxis, and instructed to seek emergency medical care if symptoms worsen. Parent verbalized understanding. 1550: Reinforced instructions to parent to seek emergency care if condition worsens. Assessment reveals hives visibly reduced, no s/s of discomfort or distress. 1551: Patient left clinic in stable condition.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Urticaria
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
denies
Vorgeschichte
denies
Andere Medikamente
denies
Allergien
parent states pt is allergic to all meat. Parent states he eats eggs regularly and denies egg allergy.
Vorherige Impfungen
-

VAERS 1736838

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge u007471

mild
Staat
TX
Alter
10,0
Geschlecht
M
Eingang
27.09.2021
Impfdatum
24.09.2021
Beginn
24.09.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
SC / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Hypersensitivity Urticaria

Symptomtext

1503: Patient returns to area, mom lifts atient?s shirt to reveal hives on back and front of trunk, neck, and on upper arms. Pt also noted to be scratching. Patient AAO, respirations even/unlabored at 20/min, child is calm with no s/s of distress. 1505: area cleared, Vital signs taken, initiated close monitoring and observation for safety. 1508: Administered Benadryl 25mg chewable tablet PO 1511: Language line called, explained to mother that hives are an allergic reaction, that the children are not in immediate danger or distress, and explained the medication administered and how it should help 1517: Vital signs taken and pt reassessed. Hives still visible, but no s/s of distress or increase in severity. Close monitoring continued. 1520: Notified Dr. of situation via phone, MD orders taken: 1. Follow SDO for moderate allergic reaction 2. Continue monitoring for 30 minutes, then evaluate ensure reaction is not progressing in severity. 1524: Onsite provider NP comes to area, evaluates patient. NP reinforces that patient is experiencing a mild reaction, and that it is safe for patient to leave clinic as reaction is not progressing in severity. 1529: Patient reassessed. Fewer hives visible, and those seen are noted to be smaller and less raised. Close monitoring continued. 1537: Program manager contacted via phone and briefed on situation. 1545: Spoke with parent again via language line iinterpreter.Educated parent on hives as an allergic reaction, medication given as treatment, s/s of anaphylaxis, and instructed to seek emergency medical care if symptoms worsen. Parent verbalized understanding. 1550: Reinforced instructions to parent to seek emergency care if condition worsens. Assessment reveals hives visibly reduced, no s/s of discomfort or distress. 1551: Patient left clinic in stable condition.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Urticaria
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
Denies
Vorgeschichte
Denies
Andere Medikamente
Denies
Allergien
parent states pt is allergic to all meat. Parent sttates he eats eggs regularly and denies egg allergy.
Vorherige Impfungen
-

VAERS 2365786

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U007471

gering
Staat
NC
Alter
-
Geschlecht
U
Eingang
12.07.2022
Impfdatum
10.05.2022
Beginn
10.05.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect route of product administration No adverse event

Symptomtext

No symptomatic side effects. No additional AE; patient was administered VARIVAX intramuscularly instead of subcutaneously.; This spontaneous report was received from a pharmacist concerning a patient of unknown age and gender. The patient's concurrent conditions, medical history, and concomitant therapies were not provided. On 10-MAY-2022, the patient received a dose of varicella virus vaccine live (Oka/Merck) injection, by intramuscular route as prophylaxis (lot number U007471 which has been verified to be valid, expiration date reported and validated as 08-MAR-2023) (dose was unknown by the reporter; strength, vaccination scheme, and anatomical site of injection were not reported) (incorrect route of product administration). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT), lot number T030955 and expiration date 23-APR-2023 (dose was unknown by the reporter). The reporter mentioned that the patient had no symptomatic side effects (no adverse event).

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect route of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2316240

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U007471

gering
Staat
IA
Alter
-
Geschlecht
U
Eingang
11.06.2022
Impfdatum
08.06.2022
Beginn
08.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect route of product administration

Symptomtext

VARIVAX was administered IM instead of SC; This spontaneous report was received from a registered nurse referring to a patient of unspecified age and gender. The patient's pertinent medical history, concurrent conditions, concomitant medications and previous drug reactions or allergies were not provided. On 08-JUN-2022, the patient was vaccinated with varicella virus vaccine live (Oka/Merck) (VARIVAX) as prophylaxis (dose, vaccine scheme, and anatomical site of vaccination were not reported; lot number U007471 has been verified to be valid, expiration date reported and established as 08-MAR-2023) administered intramuscularly instead of subcutaneously (incorrect route of product administration). No other issues or concerns were reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect route of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1954038

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U007471

gering
Staat
WV
Alter
-
Geschlecht
U
Eingang
16.12.2021
Impfdatum
05.11.2021
Beginn
08.11.2021
Tage bis Beginn
3,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions, allergies and concomitant medication were not reported. On 05-NOV-2021, the patient was vaccinated with Measles, Mumps and Rubella (wistar ra 27-3) virus vaccine, live (albumin status rHA) (M-M-R II) lot # T016352 was confirmed to be valid, expiration date 12-MAY-2022 (exact dose, route of administration, anatomical location were not reported). On 08-NOV-2021, the patient was vaccinated with varicella virus vaccine live (oka/merck)(VARIVAX) lot # U007471 was confirmed to be valid, expiration date 08-MAR-2023 (exact dose, route of administration, anatomical location were not reported) for prophylaxis ( inappropriate schedule of product administration). No adverse effects were reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1845759

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U007471

gering
Staat
CA
Alter
9,0
Geschlecht
U
Eingang
05.11.2021
Impfdatum
07.10.2021
Beginn
07.10.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered No adverse event

Symptomtext

No other AEs or PQC reported. No Additional information available.; received PROQUAD and VARlVAX at same visit; This spontaneous report was received from a medical assistant and refers to a 9-year-old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 07-OCT-2021, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) lot # U006312, expiration date 24-AUG-2022, 0.5 milliliter, subcutaneously (SQ) and varicella virus vaccine live (oka/merck) (VARIVAX) lot # U007471, expiration date 08-MAR-2023, 0.5 ml, SQ (formulations, concentrations, dose numbers and anatomical locations were not reported) for prophylaxis. Both the vaccines were administered at the same visit (overdose). No additional adverse event was reported (no adverse event).

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1787441

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U007471

gering
Staat
AZ
Alter
4,0
Geschlecht
U
Eingang
15.10.2021
Impfdatum
27.09.2021
Beginn
27.09.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

No additional AE reported; VARIVAX was administered after a temperature excursion; This spontaneous report was received from a physician and refers to a 4-year-old patient. Information regarding the patient's concurrent conditions, medical history and historical drugs was not provided. Concomitant vaccinations included Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) which did not experienced a temperature excursion. On 27-SEP-2021, the patient was vaccinated with improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) (dosage regimen was not reported), lot # U007471 and expiration date 08-MAR-2023 administered as prophylaxis. The improperly stored dose of the suspect vaccine experienced a temperature excursion of 28.56 degree fahrenheit (?F) for 44 hours and 5 minutes on an unspecified date; no previous temperature excursions were reported. No adverse symptoms were reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
M-M-R II
Allergien
-
Vorherige Impfungen
-

VAERS 1681310

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U007471

gering
Staat
IN
Alter
1,0
Geschlecht
U
Eingang
08.09.2021
Impfdatum
23.08.2021
Beginn
23.08.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered No adverse event Wrong product administered

Symptomtext

No side effects reported at this time; accidently given PROQUAD and VARlVAX instead of VARlVAX and MMR-II; accidently given PROQUAD and VARlVAX instead of VARlVAX and MMR-II; This spontaneous report was received from a medical assistant referring to a 1 year old patient of unknown gender. Information about pertinent medical history, drug reaction/allergy and concomitant medication was not provided. On 23-AUG-2021, the patient was accidently given measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) 0.5 ml (1 dose, lot # T032149, expiration date 20-MAR-2022) and varicella virus vaccine live (oka/merck) (VARIVAX) 0.5 ml (1 dose, lot # U007471, expiration date 08-MAR-2023), both intramuscularly (IM) for prophylaxis, instead of varicella virus vaccine live (oka/merck) (VARIVAX) and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (wrong product administered and accidental overdose). Therefore, the patient inadvertently received an extra dose of Varicella. No side effects reported at the time of reporting.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-